Frazier Life Sciences

Activity in this selectiongoldman-sachs-alternatives-life-sciences-c1335a4c

By stage

Series A2

Series B2

Series C+1

Biotech5

United States4

United Kingdom1

5 in this selection

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Jun 24

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries A

Role not disclosed

Apr 8

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed

Jan 9

Develops therapeutics for pulmonary diseases, specifically COPD

$200MSeries A

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed